19-Dec-2025
No headlines found.
Globe Newswire (Tue, 9-Dec 9:00 AM ET)
Globe Newswire (Tue, 25-Nov 4:15 PM ET)
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Globe Newswire (Tue, 11-Nov 9:00 AM ET)
Globe Newswire (Mon, 10-Nov 8:30 AM ET)
Globe Newswire (Thu, 6-Nov 8:30 AM ET)
Globe Newswire (Mon, 3-Nov 4:05 PM ET)
Globe Newswire (Fri, 31-Oct 9:05 AM ET)
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
Globe Newswire (Mon, 27-Oct 4:15 PM ET)
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
Globe Newswire (Tue, 14-Oct 8:00 AM ET)
Globe Newswire (Wed, 8-Oct 5:21 PM ET)
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Myriad Genetics trades on the NASDAQ stock market under the symbol MYGN.
As of December 19, 2025, MYGN stock price declined to $6.55 with 2,449,478 million shares trading.
MYGN has a beta of 1.75, meaning it tends to be more sensitive to market movements. MYGN has a correlation of 0.09 to the broad based SPY ETF.
MYGN has a market cap of $610.55 million. This is considered a Small Cap stock.
Last quarter Myriad Genetics reported $206 million in Revenue and $.00 earnings per share. This beat revenue expectation by $534,904 and exceeded earnings estimates by $.05.
In the last 3 years, MYGN traded as high as $29.30 and as low as $3.76.
The top ETF exchange traded funds that MYGN belongs to (by Net Assets): IJR, VTI, IWM, XBI, VXF.
MYGN has underperformed the market in the last year with a price return of -50.3% while the SPY ETF gained +18.1%. MYGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.7% and -7.6%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
MYGN support price is $6.46 and resistance is $6.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MYGN shares will trade within this expected range on the day.
